Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03038477
Title A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver

pancreatic ductal adenocarcinoma



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.